In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xcel Pharmaceuticals Inc.

Division of Valeant Pharmaceuticals International/Xcel Pharmaceuticals Inc.
www.xcelpharmaceuticals.com

Latest From Xcel Pharmaceuticals Inc.

Ex-Shire Team Builds New Euro-Specialty Group

Archimedes joins a growing new generation of pan-European specialty pharma, highlighting the need for a single commercial partner across Europe and the increasing alternatives to big and mid-sized pharma.
BioPharmaceutical Strategy

Pfizer/Angiosyn: Building Biotechs for Device-style Early M&A

Pfizer's acquisition of privately-held Angiosyn is basically a milestones-and-royalty-based licensing deal for the biotech's preclinical non-VEGF targeting AMD candidate. Angiosyn was designed for early M&A, much like most medical device firms of the past ten years, and this risk-sharing agreement with Pfizer may imply a new, leaner model for biotech company building.
BioPharmaceutical Strategy

Strakan: Refining Search & Development

The low-risk specialty pharmaceuticals model has never been more fashionable, in part thanks to the success of one of Europe's in-licensing pioneers, Shire. Shire's founder Harry Stratford is now having another go with Strakan, but incorporating R&D far earlier in Strakan's evolution than has been the case at Shire, thereby attempting to address the thorny question of long-term sustainability-one that Shire and other more mature in-licensing firms are currently grappling with.
BioPharmaceutical Europe

Boom or Bust, VCs Fund Their Best Bets--Cont.

Undeterred by the biotech slump, VCs are still doling out sizable rounds--and at perhaps their greatest rate ever.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Valeant Pharmaceuticals International
  • Senior Management
  • Michael T Borer, Pres. & CEO
    George Stuart, VP, Fin. & CFO
    Wendy L Martin, MD, VP, Clinical & Product Dev.
  • Contact Info
  • Xcel Pharmaceuticals Inc.
    Phone: (858) 202-2700
    6363 Greenwich Dr.
    Ste. 100
    San Diego, CA 92122
    USA
UsernamePublicRestriction

Register